A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
Hematological Oncology · 2025
DOI: 10.1002/hon.70141 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, 2025. Verfasst von Masahito Tokunaga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Imamura General Hospital, Kagoshima, Japan. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Leukemia-Lymphoma, Adult T-Cell, Ki-1 Antigen, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited.
Abstract (Originalsprache)
Adult T‐cell leukemia‐lymphoma (ATL) is a rare, aggressive malignancy prevalent in Japan, the Caribbean, and Central/South America. This multicenter retrospective study evaluated the effectiveness and safety of brentuximab vedotin with cyclophosphamide, doxorubicin, and prednisolone (BV‐CHP) in patients aged ≥ 18 years with previously untreated CD30‐positive ATL, verified through immunohistochemistry/flow cytometry, from six hospitals in Japan. Outcomes included overall response rate (ORR; primary outcome), overall survival (OS), progression‐free survival (PFS), complete response rate (CRR), disease control rate (DCR), and safety. Subgroup analyses evaluated lesion site, ATL subtype, age, and CD30 expression. Of 46 screened patients, 36 (median age 71 years; 66.7% female) were analyzed and started BV‐CHP between April 2020 and January 2024. CD30 positivity was confirmed in all patients. ORR was 86.1% (95% confidence interval [CI] 70.5–95.3), CRR 61.1% (95% CI 43.5–76.9), and DCR 91.7% (95% CI 77.5–98.3). ORR by lesion site (lymph nodes, peripheral blood, skin) was 93.8%, 90.9%, and 83.3%, respectively, by ATL subtype (acute, lymphoma) was 78.9% and 94.1%, respectively, and by age (≤ 70 years, > 70 years) was 84.6% and 87.0%, respectively. One patient with CD30 expression < 10% achieved a complete response; ORR was 73.7% in 19 patients with CD30 expression ≥ 10%. Median OS and PFS was 535 days (95% CI 343–not estimable) and 205 days (95% CI 166–279), respectively. Treatment‐emergent adverse events of any grade and grade ≥ 3 both occurred in 88.9% of patients, with neutropenia, febrile neutropenia, and thrombocytopenia being most common. Among 11 patients who underwent allogeneic stem cell transplantation, two developed acute graft‐versus‐host disease; median PFS was 234 days (95% CI 168–343), compared with 180 days (95% CI 96–279) without transplantation. BV‐CHP demonstrated high ORR and CRR across age groups and ATL subtypes with a manageable safety profile, supporting its potential use as a standard treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
- Department of Hematology, Sasebo City General Hospital, Sasebo, Japan.
- Department of Hematology, Iizuka Hospital, Iizuka, Japan.
- Department of Internal Medicine, Miyazaki Prefectural Nobeoka Hospital, Nobeoka, Japan.
- Department of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
- Department of Hematology and Cell Therapy, NHO Kyushu Cancer Center, Fukuoka, Japan.
ORCID-Profile: Masahito Tokunaga, Junya Makiyama, Motoaki Shiratsuchi, Ilseung Choi, Kiyoshi Okazuka, Atae Utsunomiya
Förderung
- Takeda Pharmaceutical Company Limited
Zitieren
APA
Tokunaga, M., Makiyama, J., Shiratsuchi, M., Toyama, T., Oka, S., Choi, I., Yoshida, T., Okazuka, K., & Utsunomiya, A. (2025). A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70141
Vancouver
Tokunaga M, Makiyama J, Shiratsuchi M, Toyama T, Oka S, Choi I, et al. A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70141
BibTeX
@article{Tokunaga2025,
author = {Tokunaga, Masahito and Makiyama, Junya and Shiratsuchi, Motoaki and Toyama, Takanori and Oka, Satoshi and Choi, Ilseung and Yoshida, Takahiro and Okazuka, Kiyoshi and Utsunomiya, Atae},
title = {A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70141}
}
EUVIMED